title: Dornase alpha and survival of patients with cystic fibrosis.
abstract: Dornase alpha can offer substantial clinical benefits to cystic fibrosis patients, but its long-term impact is as yet unknown. This article attempts to model the impact of continuous dornase alpha use on patient survival and its cost implications for the health-care provider.
authors.affiliation: Roche Products Ltd, Welwyn Garden City, Hertfordshire.
authors.forename: A M
authors.initials: AM
authors.lastname: McIntyre
mesh_terms: D003362:Cost-Benefit Analysis; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000401:mortality; D003850:Deoxyribonuclease I / Q000191:economics / Q000627:therapeutic use*; D018450:Disease Progression; D005100:Expectorants / Q000191:economics / Q000627:therapeutic use*; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D008017:Life Expectancy; D011788:Quality of Life; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D005100:Expectorants; D011994:Recombinant Proteins; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I